{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:07:14Z","timestamp":1789024034166,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Crinetics Pharmaceuticals Inc","award":["This study was funded by Crinetics Pharmaceuticals Inc"],"award-info":[{"award-number":["This study was funded by Crinetics Pharmaceuticals Inc"]}]},{"name":"Crinetics Pharmaceuticals Inc","award":["This study was funded by Crinetics Pharmaceuticals Inc"],"award-info":[{"award-number":["This study was funded by Crinetics Pharmaceuticals Inc"]}]},{"name":"Crinetics Pharmaceuticals Inc","award":["This study was funded by Crinetics Pharmaceuticals Inc"],"award-info":[{"award-number":["This study was funded by Crinetics Pharmaceuticals Inc"]}]},{"name":"Crinetics Pharmaceuticals Inc","award":["This study was funded by Crinetics Pharmaceuticals Inc"],"award-info":[{"award-number":["This study was funded by Crinetics Pharmaceuticals Inc"]}]},{"name":"Crinetics Pharmaceuticals Inc","award":["This study was funded by Crinetics Pharmaceuticals Inc"],"award-info":[{"award-number":["This study was funded by Crinetics Pharmaceuticals Inc"]}]},{"name":"Crinetics Pharmaceuticals Inc","award":["This study was funded by Crinetics Pharmaceuticals Inc"],"award-info":[{"award-number":["This study was funded by Crinetics Pharmaceuticals Inc"]}]},{"name":"Crinetics Pharmaceuticals Inc","award":["This study was funded by Crinetics Pharmaceuticals Inc"],"award-info":[{"award-number":["This study was funded by Crinetics Pharmaceuticals Inc"]}]},{"name":"Crinetics Pharmaceuticals Inc","award":["This study was funded by Crinetics Pharmaceuticals Inc"],"award-info":[{"award-number":["This study was funded by Crinetics Pharmaceuticals Inc"]}]},{"name":"Crinetics Pharmaceuticals Inc","award":["This study was funded by Crinetics Pharmaceuticals Inc"],"award-info":[{"award-number":["This study was funded by Crinetics Pharmaceuticals Inc"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To quantify the severity, frequency of symptom exacerbations, and associated life impact of acromegaly symptoms in patients treated with injected depot somatostatin receptor ligands (SRLs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients receiving depot SRLs completed daily 24-hour recall surveys for 3 months. The daily surveys assessed the severity of 7 core symptoms and 2 additional symptoms on numeric scales (0\u201310). Symptom exacerbation was defined as a \u2265\u20092-point increase in any symptom score, comparing the current 2-day average with the prior 2-day average. Patients completed a final survey assessing 3-month recall of symptom severity and daily functioning, treatment satisfaction, and healthcare resource utilization (HCRU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis population included 31 patients: mean (SD) age was 53.4 (13.6) years; 24 (77.4%) were female; 15 (48.4%) were receiving SRL monotherapy and 16 (51.6%) SRL plus non-SRL therapy. Three-month recall overestimated symptom severity relative to daily ratings and did not capture exacerbation frequency. Symptom exacerbations assessed via daily surveys occurred, on average, on 32.1% of days (&gt;\u20092 days\/week) throughout the injection cycle. Greater total and individual symptom severity and exacerbation frequency were related to greater life interference, including impaired daily activities, reduced work productivity, reduced treatment satisfaction, diminished life satisfaction, and increased HCRU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with acromegaly treated with injected depot SRLs, symptom exacerbations occurred frequently. Symptom severity and exacerbation frequency were associated with impaired daily functioning and reduced life satisfaction. A simple daily symptom assessment provides clinically meaningful information about adequacy of disease control that is not captured by longer-term recall.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-026-01732-3","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:13:19Z","timestamp":1784823199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptom severity and exacerbation frequency in medically treated patients with acromegaly"],"prefix":"10.1007","volume":"29","author":[{"given":"Eliza B.","family":"Geer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Clemmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Sisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Koobatian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janetricks C.","family":"Okeyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany P.","family":"Quock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Colzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"19","key":"1732_CR1","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"Giustina A, Colao A (2025) Acromegaly. N Engl J Med 393(19):1926\u20131939. https:\/\/doi.org\/10.1056\/NEJMra2409076","journal-title":"N Engl J Med"},{"issue":"11","key":"1732_CR2","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10(11):804\u2013826. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1732_CR3","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00701-016-2903-4","volume":"158","author":"D Starnoni","year":"2016","unstructured":"Starnoni D, Daniel RT, Marino L, Pitteloud N, Levivier M, Messerer M (2016) Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochir (Wien) 158(11):2109\u20132121. https:\/\/doi.org\/10.1007\/s00701-016-2903-4","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"1732_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3171\/2021.11.JNS212137","volume":"137","author":"X Guo","year":"2022","unstructured":"Guo X, Zhang R, Zhang D, Wang Z, Gao L, Yao Y, Deng K, Bao X, Feng M, Xu Z, Yang Y, Lian W, Wang R, Ma W, Xing B (2022) Determinants of immediate and long-term remission after initial transsphenoidal surgery for acromegaly and outcome patterns during follow-up: a longitudinal study on 659 patients. J Neurosurg 137(3):618\u2013628. https:\/\/doi.org\/10.3171\/2021.11.JNS212137","journal-title":"J Neurosurg"},{"issue":"11","key":"1732_CR5","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","volume":"21","author":"S Melmed","year":"2025","unstructured":"Melmed S, di Filippo L, Fleseriu M, Mercado M, Karavitaki N, Gurnell M, Salvatori R, Tsagarakis S, Losa M, Maffei P, Pereira AM, Geer EB, Katznelson L, van der Lely AJ, Bollerslev J, Esposito D, Webb SM, Zatelli MC, Valassi E, Neggers S, Chanson P, Ho KKY, Ioachimescu AG, Biller BMK, Samson SL, Kaiser UB, Schilbach K, Luque RM, Casanueva FF, Shimon I, Boguszewski CL, Biermasz N, Colao A, Pirchio R, Lamberts SWJ, Kadioglu P, Buchfelder M, Frara S, Chiloiro S, Petersenn S, Gadelha MR, Puig-Domingo M, Luger A, Brue T, Beckers A, Ferone D, Clemmons DR, Greenman Y, Marazuela M, Mortini P, Strasburger CJ, Giustina A (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol 21(11):718\u2013737. https:\/\/doi.org\/10.1038\/s41574-025-01148-2","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1732_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667\u2013678. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"1732_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1530\/EJE-15-1042","volume":"174","author":"CJ Strasburger","year":"2016","unstructured":"Strasburger CJ, Karavitaki N, St\u00f6rmann S, Trainer PJ, Kreitschmann-Andermahr I, Droste M, Korbonits M, Feldmann B, Zopf K, Sanderson VF, Schwicker D, Gelbaum D, Haviv A, Bidlingmaier M, Biermasz NR (2016) Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol 174(3):355\u2013362. https:\/\/doi.org\/10.1530\/EJE-15-1042","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1732_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","volume":"20","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Liu S, Mathias SD, Gelbaum D, Shi L (2020) Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord 20(1):117. https:\/\/doi.org\/10.1186\/s12902-020-00595-4","journal-title":"BMC Endocr Disord"},{"key":"1732_CR9","doi-asserted-by":"publisher","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","volume":"12","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD, Ludlam WH, Haviv A, Gilgun-Sherki Y, Mathias SD (2021) Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front Endocrinol (Lausanne) 12:627711. https:\/\/doi.org\/10.3389\/fendo.2021.627711","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1732_CR10","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/MPA.0b013e318279d552","volume":"42","author":"AE Boyd","year":"2013","unstructured":"Boyd AE, DeFord LL, Mares JE, LC C, Garris JL, Dagohoy CG, Boving VG, Brook JP, Phan A, Yao JC (2013) Improving the success rate of gluteal intramuscular injections. Pancreas 42(5):878\u2013882. https:\/\/doi.org\/10.1097\/MPA.0b013e318279d552","journal-title":"Pancreas"},{"key":"1732_CR11","unstructured":"Sisco J, Palaty C (2021) Voice of the patient: living with acromegaly. Paper presented at the Acromegaly Community Virtual Externally-Led Patient-Focused Drug Development Meeting, Virtual, January 21, 2021"},{"issue":"4","key":"1732_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ejendo\/lvaf200","volume":"193","author":"I Remba-Shapiro","year":"2025","unstructured":"Remba-Shapiro I, Schweizer JROL, Moscona-Nissan A, Liebert KJP, Jones PS, Schilbach K, Rojas JN, Adams M, Cheng VO, Tritos NA, Bidlingmaier M, Nachtigall LB (2025) Insulin-like growth factor-I and symptoms of acromegaly according to time since somatostatin receptor ligand injection. Eur J Endocrinol 193(4):564\u2013573. https:\/\/doi.org\/10.1093\/ejendo\/lvaf200","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1732_CR13","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1210\/jc.2011-1645","volume":"96","author":"J Tiemensma","year":"2011","unstructured":"Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR (2011) Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab 96(11):3550\u20133558. https:\/\/doi.org\/10.1210\/jc.2011-1645","journal-title":"J Clin Endocrinol Metab"},{"key":"1732_CR14","doi-asserted-by":"publisher","first-page":"101422","DOI":"10.1016\/j.ghir.2021.101422","volume":"60\u201361","author":"S Siegel","year":"2021","unstructured":"Siegel S, Kirstein CF, Schr\u00f6der B, Unger N, Kreitschmann-Andermahr I (2021) Illness-related burden, personal resources and need for support in patients with acromegaly: results of a focus group analysis. Growth Horm IGF Res 60\u201361:101422. https:\/\/doi.org\/10.1016\/j.ghir.2021.101422","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"1732_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1046\/j.1365-2265.2000.01134.x","volume":"53","author":"P Chanson","year":"2000","unstructured":"Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jim\u00e9nez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM (2000) Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 53(5):577\u2013586. https:\/\/doi.org\/10.1046\/j.1365-2265.2000.01134.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1732_CR16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","volume":"66","author":"M Mercado","year":"2007","unstructured":"Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J, SMS995B2401 Study Group (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66(6):859\u2013868. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02825.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1732_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/BF03346453","volume":"32","author":"G Lombardi","year":"2009","unstructured":"Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arrnaldi G, Arosio M, Chiarini V, Cozzi R, Grottoli S, Mantero F, Bogazzi F, Terzolo M, Tita P, Boscani PF, Colao A (2009) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 32(3):202\u2013209. https:\/\/doi.org\/10.1007\/BF03346453","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1732_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11102-015-0693-y","volume":"19","author":"PJ Caron","year":"2016","unstructured":"Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM, PRIMARYS Investigators Group (2016) Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 19(2):149\u2013157. https:\/\/doi.org\/10.1007\/s11102-015-0693-y","journal-title":"Pituitary"},{"issue":"16","key":"1732_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA (2000) Treatment of acromegaly with the growth hormone\u2013receptor antagonist pegvisomant. N Engl J Med 342(16):1171\u20131177. https:\/\/doi.org\/10.1056\/NEJM200004203421604","journal-title":"N Engl J Med"},{"issue":"1","key":"1732_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41687-023-00541-7","volume":"7","author":"S Martin","year":"2023","unstructured":"Martin S, Bender RH, Krasner A, Marmon T, Monahan M, Nelson L (2023) Development and evaluation of the Acromegaly Symptom Diary. J Patient Rep Outcomes 7(1):15. https:\/\/doi.org\/10.1186\/s41687-023-00541-7","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"1732_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s41687-025-00965-3","volume":"9","author":"M Koobatian","year":"2025","unstructured":"Koobatian M, Sisco J, Okeyo JC, Krasner A, Quock TP (2025) Real-world burden of disease, treatment, and healthcare resource utilization in acromegaly: a quantitative survey of patient experiences. J Patient Rep Outcomes 9(1):140. https:\/\/doi.org\/10.1186\/s41687-025-00965-3","journal-title":"J Patient Rep Outcomes"},{"key":"1732_CR22","unstructured":"US Department of Health and Human Services (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf Accessed May 16 2025"},{"issue":"1","key":"1732_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1210\/clinem\/dgae385","volume":"110","author":"MR Gadelha","year":"2025","unstructured":"Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA, Boguszewski CL, Buchfelder M, Shimon I, Raverot G, T\u00f3th M, Mez\u0151si E, Doknic M, Fan X, Clemmons D, Trainer PJ, Struthers RS, Krasner A, Biller BMK (2025) Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine. J Clin Endocrinol Metab 110(1):228\u2013237. https:\/\/doi.org\/10.1210\/clinem\/dgae385","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1732_CR24","doi-asserted-by":"publisher","first-page":"e1050","DOI":"10.1210\/clinem\/dgaf579","volume":"111","author":"BMK Biller","year":"2026","unstructured":"Biller BMK, Casagrande A, Elenkova A, Boguszewski CL, Jallad RS, Hu B, Hubina E, Fazeli PK, Fleseriu M, Snyder PJ, Strasburger CJ, Bidlingmaier M, Zhao Y, Soares B, Trainer PJ, Struthers RS, Krasner A, Gadelha MR (2026) Rapid and sustained response of biochemically uncontrolled acromegaly to once-daily oral paltusotine treatment. J Clin Endocrinol Metab 111(4):e1050\u2013e1063. https:\/\/doi.org\/10.1210\/clinem\/dgaf579","journal-title":"J Clin Endocrinol Metab"},{"key":"1732_CR25","unstructured":"Palsonify (paltusotine) tablets, for oral use [package insert]. Crinetics Pharmaceuticals, Inc. (2025)"},{"issue":"4","key":"1732_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11102-023-01322-7","volume":"26","author":"TNA Slagboom","year":"2023","unstructured":"Slagboom TNA, van Bunderen CC, De Vries R, Bisschop PH, Drent ML (2023) Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines. Pituitary 26(4):319\u2013332. https:\/\/doi.org\/10.1007\/s11102-023-01322-7","journal-title":"Pituitary"},{"issue":"2","key":"1732_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11102-025-01509-0","volume":"28","author":"AT Matthesen","year":"2025","unstructured":"Matthesen AT, Rosendal C, Christensen EH, Beckmann H, Klit F\u00d8, Nikontovic A, Bizik G, Vestergaard P, Dal J (2025) Psychiatric morbidity in acromegaly: a cohort study and meta-analysis of the literature. Pituitary 28(2):42. https:\/\/doi.org\/10.1007\/s11102-025-01509-0","journal-title":"Pituitary"},{"issue":"3","key":"1732_CR28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/ejendo\/lvag047","volume":"194","author":"B Cangiano","year":"2026","unstructured":"Cangiano B, Corbetta M, Premoli C, Soranna D, Vitale G, Grottoli S, Cambria V, Maffei P, Dassie F, Cannav\u00f2 S, Ragonese M, Zambon A, Bonomi M, Persani L, Fatti LM, Scacchi M, PRO-ACRO study group on Motor Disability in Acromegaly of the Italian Society of Endocrinology (SIE) (2026) Progression of acromegalic joint and psychological complications according to sex, treatments, and disease control. Eur J Endocrinol 194(3):404\u2013412. https:\/\/doi.org\/10.1093\/ejendo\/lvag047","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1732_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-026-01685-7","volume":"29","author":"G Martino","year":"2026","unstructured":"Martino G, Silvestro O, Ferra\u00f9 F, Cannav\u00f2 S (2026) Recent progress in the understanding of psychological complications of acromegaly: toward a longitudinal clinical phenotype. Pituitary 29(3):82. https:\/\/doi.org\/10.1007\/s11102-026-01685-7","journal-title":"Pituitary"},{"issue":"4","key":"1732_CR30","doi-asserted-by":"publisher","first-page":"dgz096","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105(4):dgz096. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1732_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/jim-2017-000570","volume":"66","author":"S Liu","year":"2018","unstructured":"Liu S, Adelman DT, Xu Y, Sisco J, Begelman SM, Webb SM, Badia X, Thethi TK, Fonseca V, Shi L (2018) Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. J Investig Med 66(3):653\u2013660. https:\/\/doi.org\/10.1136\/jim-2017-000570","journal-title":"J Investig Med"},{"issue":"4","key":"1732_CR32","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1210\/jc.2004-2009","volume":"90","author":"JJ Puder","year":"2005","unstructured":"Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90(4):1972\u20131978. https:\/\/doi.org\/10.1210\/jc.2004-2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 1","key":"1732_CR33","doi-asserted-by":"publisher","first-page":"A723","DOI":"10.1210\/jendso\/bvad114.1355","volume":"7","author":"EB Geer","year":"2023","unstructured":"Geer EB, Huang W, Gordon MB, Yuen KCJ, Lubitz SE, Salvatori R, Fleseriu M, Ioachimescu AG, Christofides EA, Sisco J, Mathias SD, Crompton JA, Molitch ME (2023) Matched physician- and patient-reported responses of acromegaly symptom control: comparisons from the MACRO registry [abstract SAT622]. J Endocr Soc 7(suppl 1):A723. https:\/\/doi.org\/10.1210\/jendso\/bvad114.1355","journal-title":"J Endocr Soc"},{"issue":"4","key":"1732_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1530\/EJE-17-0996","volume":"178","author":"CJ Strasburger","year":"2018","unstructured":"Strasburger CJ, Mattsson A, Wilton P, Aydin F, Hey-Hadavi J, Biller BMK (2018) Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant. Eur J Endocrinol 178(4):321\u2013329. https:\/\/doi.org\/10.1530\/EJE-17-0996","journal-title":"Eur J Endocrinol"},{"key":"1732_CR35","doi-asserted-by":"publisher","first-page":"1516131","DOI":"10.3389\/fendo.2025.1516131","volume":"16","author":"SN Shah","year":"2025","unstructured":"Shah SN, Yuen KCJ, Bonert V, Huang W, Sisco J, Palaty C, Dancel-Manning K, Agrawal N (2025) Patient perspectives on acromegaly disease burden: insights from a community meeting. Front Endocrinol (Lausanne) 16:1516131. https:\/\/doi.org\/10.3389\/fendo.2025.1516131","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1732_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","volume":"23","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D, Liu S, Mathias SD, Shi L (2020) Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary 23(2):140\u2013148. https:\/\/doi.org\/10.1007\/s11102-019-01013-2","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01732-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01732-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01732-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:42:42Z","timestamp":1789022562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01732-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1732"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01732-3","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Spacing errors in article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.B.G. reports serving as a consultant for Camurus, Crinetics Pharmaceuticals, Inc., HRA Pharma\/Esteve, Recordati, and Xeris; and serving as an investigator for research grants to MSKCC from Recordati and Sparrow; she is an Associate Editor for\u00a0\n                      Pituitary\n                      and played no role in the Journal\u2019s evaluation of this manuscript. D.R.C reports serving as a consultant for AstraZeneca, Crinetics Pharmaceuticals, Inc., and Novo Nordisk. J.S. reports serving as a consultant for Alexion, Camurus, Chiesi, Debiopharm, and Recordati; and serving on advisory boards for Crinetics Pharmaceuticals, Inc., and Pfizer. M.K. and T.P.Q. were employees of Crinetics Pharmaceuticals, Inc., at the time this work was conducted. J.C.O., Y.W., R.C., and A.K. are employees and shareholders of Crinetics Pharmaceuticals, Inc.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"127"}}